MedPath

Comparison of two Treatment modalities in external genital warts

Phase 3
Conditions
Health Condition 1: A630- Anogenital (venereal) warts
Registration Number
CTRI/2024/05/067393
Lead Sponsor
GMC Amritsar Punjab
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Newly diagnosed cases for atleast 3 months duration

Give informed consent

Exclusion Criteria

patients having unrealistic expectations or having psychiatric illness

patients with renal, cardiac or hepatic disorders

immunocompromised patients

Pregnancy and lactating mothers

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
umber of cases with complete clearance <br/ ><br>Time taken for complete clearance <br/ ><br>Mean change in number of lesions <br/ ><br>recurrences <br/ ><br>adverse events <br/ ><br>Timepoint: at baseline at 4 weeks at 8 weeks, 12 weeks and 16 weeks with a follow up period of 3 months <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
Treatment sessions required for complete clearance of genital warts. <br/ ><br>Time taken for complete clearance of genital warts. <br/ ><br>Mean change from the baseline <br/ ><br>recurrences and <br/ ><br>adverse effects <br/ ><br>Timepoint: 20 weeks <br/ ><br> 24 weeks <br/ ><br> 28 weeks <br/ ><br> 32 weeks post treatment follow up period
© Copyright 2025. All Rights Reserved by MedPath